Literature DB >> 19388010

3-hydroxy 3-methylglutaryl coenzyme A reductase increase is essential for rat muscle differentiation.

Chiara Martini1, Laura Trapani, Laura Narciso, Maria Marino, Anna Trentalance, Valentina Pallottini.   

Abstract

3-Hydroxy 3-methylglutaryl coenzyme A reductase (HMG-CoAR) is the key and rate-limiting enzyme of cholesterol biosynthetic pathway. Although HMG-CoAR activity has already been related to the differentiation of some cellular lines there are no studies that analyze the role of HMG-CoAR, and the pathway it is involved with in a fully characterized muscle differentiation model. Thus, the aim of this work is to evaluate such role and delineate the pathway involved in foetal rat myoblasts (L6) induced to differentiate by insulin -- a standard and feasible model of the myogenic process. The results obtained by biochemical and morphological approaches demonstrate that (i) HMG-CoAR increase is crucial for differentiation induction, (ii) p21waf, whose increase is a necessary requisite for differentiation to occur, rises downstream HMG-CoAR activation, (iii) the main role of p38/MAPK as key regulator also for HMG-CoAR. Pathologies characterized by muscle degeneration might benefit from therapeutic programmes committed to muscle function restoration, such as modulation and planning myoblast differentiation. Thus, the important role of HMG-CoAR in muscular differentiation providing new molecular basis for the control of muscle development can help in the design of therapeutic treatment for diseases characterized by the weakening of muscular fibers and aging-related disorders (sarcopenia).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19388010     DOI: 10.1002/jcp.21810

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  7 in total

1.  Biphasic regulation of intracellular calcium by gemfibrozil contributes to inhibiting L6 myoblast differentiation: implications for clinical myotoxicity.

Authors:  Aiming Liu; Julin Yang; Frank J Gonzalez; Gary Q Cheng; Renke Dai
Journal:  Chem Res Toxicol       Date:  2010-12-22       Impact factor: 3.739

Review 2.  Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis.

Authors:  Andrew L Mammen
Journal:  Nat Rev Neurol       Date:  2011-06-08       Impact factor: 42.937

Review 3.  The impact of statins on physical activity and exercise capacity: an overview of the evidence, mechanisms, and recommendations.

Authors:  Allyson M Schweitzer; Molly A Gingrich; Thomas J Hawke; Irena A Rebalka
Journal:  Eur J Appl Physiol       Date:  2020-04-04       Impact factor: 3.078

Review 4.  Antilipidemic Drug Therapy Today and in the Future.

Authors:  Werner Kramer
Journal:  Handb Exp Pharmacol       Date:  2016

Review 5.  Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations.

Authors:  Albert Selva-O'Callaghan; Marcelo Alvarado-Cardenas; Iago Pinal-Fernández; Ernesto Trallero-Araguás; José Cesar Milisenda; María Ángeles Martínez; Ana Marín; Moisés Labrador-Horrillo; Cándido Juárez; Josep María Grau-Junyent
Journal:  Expert Rev Clin Immunol       Date:  2018-02-23       Impact factor: 4.473

6.  Simvastatin Impairs the Inflammatory and Repair Phases of the Postinjury Skeletal Muscle Regeneration.

Authors:  Iwona Otrocka-Domagała; Katarzyna Paździor-Czapula; Tomasz Maślanka
Journal:  Biomed Res Int       Date:  2018-11-04       Impact factor: 3.411

Review 7.  Pathophysiological Mechanisms and Treatment of Dermatomyositis and Immune Mediated Necrotizing Myopathies: A Focused Review.

Authors:  Renske G Kamperman; Anneke J van der Kooi; Marianne de Visser; Eleonora Aronica; Joost Raaphorst
Journal:  Int J Mol Sci       Date:  2022-04-13       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.